Once the patient is randomized to either of the 2 groups using computer-generated randomization blocks, the hospital pharmacist would provide the appropriate medications. The treating ophthalmologist, microbiologist and patients will be masked to the drug by using similar vials. The experimental group (Group 1) will receive 1% voriconazole eye drop (Aurolab, Madurai, India) + 5% Natamycin ophthalmic suspension eye drop hourly (USP 5% Natamet, M.J. Pharmaceuticals, Mumbai, India).
The subjects will be hospitalized for at least 4 days with medications given by the ward nurse.
Patients will be followed up every week after being discharged until complete resolution is noted.

Once the patient is randomized to either of the 2 groups using computer-generated randomization blocks, the hospital pharmacist would provide the appropriate medications. The treating ophthalmologist, microbiologist and patients will be masked to the drug by using similar vials. The placebo group (Group 2) will receive Vehicle eye drops + 5% Natamycin ophthalmic suspension every hour (USP 5% Natamet, M.J. Pharmaceuticals, Mumbai, India).
The subjects will be hospitalized for at least 4 days with medications given by the ward nurse.
Patients will be followed up every week after being discharged until complete resolution is noted.

Infection, Fungal

Group 1 Natamycin 5% Suspension + voriconazole 1% eye drops; Group 2 Natamycin 5% Suspension + Vehicle eye drops

GMRV Campus LV Prasad Eye Insitute

Combination Treatment of 5% Natamycin and 1% Voriconazole in Fungal Keratitis

Combination Treatment of 5% Natamycin and 1% Voriconazole in Fungal Keratitis: a Prospective Randomized Double Masked Clinical Trial

Primary End point:
Complete success: Complete resolution of the infiltrate with formation of a scar on medical treatment alone Partial success: Complete resolution of the infiltrate on medical treatment and use of cyanoacrylate glue and bandage contact lens Failure: Worsening of the ulcer necessitating therapeutic penetrating keratoplasty or evisceration

improvement in best corrected visual acuity

Charitha

L.V. Prasad Eye Institute

HIV positive patients on nevirapine containing regimen, taking Moringa oleifera leaf powder

HIV positive patients on efavirenz containing regimen, taking Moringa oleifera

HIV positive patients on nevirapine containing regimen, taking Moringa oleifera leaf powder
Moringa oleifera: leaf powder, 1.85g once daily as hard gelatin capsules

Nevirapine

HIV positive patients on efavirenz containing regimen, taking Moringa oleifera
Moringa oleifera: leaf powder, 1.85g once daily as hard gelatin capsules

Efavirenz

Total

Sex: Female, Male

Weight

Area under the plasma concentration time curve, determined using a non-compartmental approach by means of the Phoenix WinNonlin software application. Time points for sample collection were 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h

HIV positive patients on nevirapine containing regimen, taking Moringa oleifera leaf powder
Moringa oleifera: leaf powder

HIV positive patients on efavirenz containing regimen, taking Moringa oleifera
Moringa oleifera: leaf powder

plasma concentration 12h post dose, determined using a non-compartmental approach by means of the Phoenix WinNonlin software application. Time points for sample collection were 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h

C12h

Maximum plasma concentration post does, determined using a non-compartmental approach by means of the Phoenix WinNonlin software application. Time points for sample collection were 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h

Cmax

HIV positive patients on efavirenz containing regimen, taking Moringa oleifera leaf powder

Washout Day 0

Baseline Day 22

Day 35

Tsitsi G Monera-Penduka

leaf powder, 1.85g once daily, hard gelatin capsules

Moringa oleifera

Efavirenz 600mg

Nevirapine 200Mg Oral Tablet

Parirenyatwa Hospital OI Clinic

Moringa Oleifera- Antiretroviral Pharmacokinetic Drug Interaction

Effect of Moringa Oleifera (Moringa, Drumstick/Horseradish Tree) on The Pharmacokinetics of Efavirenz and Nevirapine In-vivo.

Tsitsi Grace Monera

Lecturer

University of Zimbabwe

State University of New York at Buffalo

Biomedical Research and Training Institute

Kyo-Dophilus (5x109 bacteria/capsule, twice a day, 1 in the morning, 1 in the evening)

potato/antifúngico

Combination Treatment of 5% Natamycin and 1% Voriconazole in Fungal Keratitis

Moringa Oleifera- Antiretroviral Pharmacokinetic Drug Interaction

Effects of Probiotics in Patients With Ulcerative Colitis

La base de datos de hierbas medicinales más completa respaldada por la ciencia